Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure

Hematopoietic stem cell (HSC) self-renewal and lineage output are orchestrated by multiple regulatory layers, including RNA modifications. N6-methyladenosine (m6A) is an abundant modification found in RNAs which affects the translation and stability of modified transcripts. The effects of m6A are de...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 134; no. Supplement_1; p. 450
Main Authors Gao, Yimeng, Vasic, Radovan, Song, Yuanbin, Teng, Rhea, Gbyli, Rana, Biancon, Giulia, Nelakanti, Raman, Kudo, Eriko, Liu, Wei, Ardasheva, Anastasia, Fu, Xiaoying, Wang, Xiaman, Joshi, Poorval, Dura, Burak, Lee, Veronica, Viero, Gabriella, Iwasaki, Akiko, Fan, Rong, Xiao, Andrew, Flavell, Richard, Li, Hua-Bing, Tebaldi, Toma, Halene, Stephanie
Format Journal Article
LanguageEnglish
Published Elsevier Inc 13.11.2019
Online AccessGet full text

Cover

Loading…
Abstract Hematopoietic stem cell (HSC) self-renewal and lineage output are orchestrated by multiple regulatory layers, including RNA modifications. N6-methyladenosine (m6A) is an abundant modification found in RNAs which affects the translation and stability of modified transcripts. The effects of m6A are determined by m6A writers (install m6A), erasers (remove m6A) and readers (recognize m6A). In embryonic stem cells, deletion of the m6A writer METTL3 enforces a naïve pluripotent state. This raises the question of whether m6A RNA methylation analogously regulates stem cell self-renewal and differentiation in somatic stem cells such as HSCs. Using a Vav-Cre/Mettl3 (VCM3) hematopoietic-specific knockout mouse model, we show that loss of the RNA m6A writer METTL3 in fetal HSCs results in hematopoietic failure and perinatal lethality. At E14.5 (FL) hematopoiesis loss of Mettl3/m6A results in hematopoietic failure with expansion of Lin-Sca-1+c-Kit+ (LSK) hematopoietic stem and progenitor cells (HSPCs) that are defective in the production of progenitors and mature blood cells, as evidenced by failure to rescue lethally irradiated congenic recipient mice in transplant experiments. The relative defect I hematopoiesis was further demonstrated by competitive transplant experiments, in which transplanted KO FL were consistently out-competed by WT FL. Interestingly, BrdU/7AAD labeling reveals a significant proliferative defect with reduced BrdU uptake in VCM3 KO FL cells, and specifically in Lin-c-Kit+Sca-1- (LK) progenitor cells. RNA-seq analysis of FL LSK cells reveals that loss of m6A results in upregulation of multiple 2‘-5‘-oligoadenylate synthetase (OAS) family genes. Interestingly, the majority of OAS family genes are not m6A modified in several m6A sequencing data sets. We therefore hypothesized that the OAS genes might be regulated at the transcriptional level. We performed cleavage under targets and release using nuclease (CUT&RUN) analysis and found that OAS family genes are transcriptionally activated, as evidenced by significant increase in H3K4 trimethylation (H3K4me3) at their respective promoter regions. The OAS family genes are activated by the presence of double stranded RNA (dsRNA), which can arise either endogenously or as a pathogen-associated trigger of the innate immune system in the context of viral infection. The dsRNA response includes three major response mechanisms. First, OAS genes facilitate RNase L dimerization, which mediates cleavage of cellular tRNA and rRNA, resulting in translation and proliferation arrest. Second, activation of the PKR/eIF2a pathway also results in translation arrest. Lastly, activation of the MDA-5/RIG-I/MAVS response induces interferon signaling, which further limits cellular proliferation. Staining of VCM3 WT & KO FL cells with the dsRNA-specific J2 antibody directly demonstrated significant accumulation of dsRNA in KO FL cells. We further demonstrated activation of the OAS/RNaseL axis in KO cells by quantification of tRNA-His-36 cleavage, which acts as a sensitive marker of RNase L activity. Phosphorylation of both PKR and eIF2a in KO cells demonstrated enhanced activity of this pathway. Lastly, we found a significant upregulation of interferon pathway genes in KO cells, and demonstrated that CRISPR mediated knockout of Mavs in VCM3 KO FL cells diminishes the activity of interferon response genes and rescues the Mettl3 KO phenotype in colony forming unit (CFU) assays. These results suggest that in the absence of m6A, endogenous dsRNA formation is enhanced, resulting in an associated inflammatory response which partially accounts for the hematopoietic defect observed in Mettl3 KO mice. In conclusion, our study suggests a novel, protective role for the m6A RNA modification in preventing endogenous dsRNA formation and aberrant activation of a detrimental innate immune response during mammalian hematopoietic development. Fan:IsoPlexis: Other: served on the scientific discovery board, Patents & Royalties; Singleron Biotechnologies: Other: served on the Scientific Advisory Board; BioTechne: Other: served on the Scientific Advisory Board. Flavell:Rheos Biomedicines: Equity Ownership; GSK: Consultancy; Artizan Biosciences: Equity Ownership; Troy: Equity Ownership; SMOC: Equity Ownership; Zai labs: Consultancy.
AbstractList Hematopoietic stem cell (HSC) self-renewal and lineage output are orchestrated by multiple regulatory layers, including RNA modifications. N6-methyladenosine (m6A) is an abundant modification found in RNAs which affects the translation and stability of modified transcripts. The effects of m6A are determined by m6A writers (install m6A), erasers (remove m6A) and readers (recognize m6A). In embryonic stem cells, deletion of the m6A writer METTL3 enforces a naïve pluripotent state. This raises the question of whether m6A RNA methylation analogously regulates stem cell self-renewal and differentiation in somatic stem cells such as HSCs. Using a Vav-Cre/Mettl3 (VCM3) hematopoietic-specific knockout mouse model, we show that loss of the RNA m6A writer METTL3 in fetal HSCs results in hematopoietic failure and perinatal lethality. At E14.5 (FL) hematopoiesis loss of Mettl3/m6A results in hematopoietic failure with expansion of Lin-Sca-1+c-Kit+ (LSK) hematopoietic stem and progenitor cells (HSPCs) that are defective in the production of progenitors and mature blood cells, as evidenced by failure to rescue lethally irradiated congenic recipient mice in transplant experiments. The relative defect I hematopoiesis was further demonstrated by competitive transplant experiments, in which transplanted KO FL were consistently out-competed by WT FL. Interestingly, BrdU/7AAD labeling reveals a significant proliferative defect with reduced BrdU uptake in VCM3 KO FL cells, and specifically in Lin-c-Kit+Sca-1- (LK) progenitor cells. RNA-seq analysis of FL LSK cells reveals that loss of m6A results in upregulation of multiple 2'-5'-oligoadenylate synthetase (OAS) family genes. Interestingly, the majority of OAS family genes are not m6A modified in several m6A sequencing data sets. We therefore hypothesized that the OAS genes might be regulated at the transcriptional level. We performed cleavage under targets and release using nuclease (CUT&RUN) analysis and found that OAS family genes are transcriptionally activated, as evidenced by significant increase in H3K4 trimethylation (H3K4me3) at their respective promoter regions. The OAS family genes are activated by the presence of double stranded RNA (dsRNA), which can arise either endogenously or as a pathogen-associated trigger of the innate immune system in the context of viral infection. The dsRNA response includes three major response mechanisms. First, OAS genes facilitate RNase L dimerization, which mediates cleavage of cellular tRNA and rRNA, resulting in translation and proliferation arrest. Second, activation of the PKR/eIF2a pathway also results in translation arrest. Lastly, activation of the MDA-5/RIG-I/MAVS response induces interferon signaling, which further limits cellular proliferation. Staining of VCM3 WT & KO FL cells with the dsRNA-specific J2 antibody directly demonstrated significant accumulation of dsRNA in KO FL cells. We further demonstrated activation of the OAS/RNaseL axis in KO cells by quantification of tRNA-His-36 cleavage, which acts as a sensitive marker of RNase L activity. Phosphorylation of both PKR and eIF2a in KO cells demonstrated enhanced activity of this pathway. Lastly, we found a significant upregulation of interferon pathway genes in KO cells, and demonstrated that CRISPR mediated knockout of Mavs in VCM3 KO FL cells diminishes the activity of interferon response genes and rescues the Mettl3 KO phenotype in colony forming unit (CFU) assays. These results suggest that in the absence of m6A, endogenous dsRNA formation is enhanced, resulting in an associated inflammatory response which partially accounts for the hematopoietic defect observed in Mettl3 KO mice. In conclusion, our study suggests a novel, protective role for the m6A RNA modification in preventing endogenous dsRNA formation and aberrant activation of a detrimental innate immune response during mammalian hematopoietic development.
Hematopoietic stem cell (HSC) self-renewal and lineage output are orchestrated by multiple regulatory layers, including RNA modifications. N6-methyladenosine (m6A) is an abundant modification found in RNAs which affects the translation and stability of modified transcripts. The effects of m6A are determined by m6A writers (install m6A), erasers (remove m6A) and readers (recognize m6A). In embryonic stem cells, deletion of the m6A writer METTL3 enforces a naïve pluripotent state. This raises the question of whether m6A RNA methylation analogously regulates stem cell self-renewal and differentiation in somatic stem cells such as HSCs. Using a Vav-Cre/Mettl3 (VCM3) hematopoietic-specific knockout mouse model, we show that loss of the RNA m6A writer METTL3 in fetal HSCs results in hematopoietic failure and perinatal lethality. At E14.5 (FL) hematopoiesis loss of Mettl3/m6A results in hematopoietic failure with expansion of Lin-Sca-1+c-Kit+ (LSK) hematopoietic stem and progenitor cells (HSPCs) that are defective in the production of progenitors and mature blood cells, as evidenced by failure to rescue lethally irradiated congenic recipient mice in transplant experiments. The relative defect I hematopoiesis was further demonstrated by competitive transplant experiments, in which transplanted KO FL were consistently out-competed by WT FL. Interestingly, BrdU/7AAD labeling reveals a significant proliferative defect with reduced BrdU uptake in VCM3 KO FL cells, and specifically in Lin-c-Kit+Sca-1- (LK) progenitor cells. RNA-seq analysis of FL LSK cells reveals that loss of m6A results in upregulation of multiple 2‘-5‘-oligoadenylate synthetase (OAS) family genes. Interestingly, the majority of OAS family genes are not m6A modified in several m6A sequencing data sets. We therefore hypothesized that the OAS genes might be regulated at the transcriptional level. We performed cleavage under targets and release using nuclease (CUT&RUN) analysis and found that OAS family genes are transcriptionally activated, as evidenced by significant increase in H3K4 trimethylation (H3K4me3) at their respective promoter regions. The OAS family genes are activated by the presence of double stranded RNA (dsRNA), which can arise either endogenously or as a pathogen-associated trigger of the innate immune system in the context of viral infection. The dsRNA response includes three major response mechanisms. First, OAS genes facilitate RNase L dimerization, which mediates cleavage of cellular tRNA and rRNA, resulting in translation and proliferation arrest. Second, activation of the PKR/eIF2a pathway also results in translation arrest. Lastly, activation of the MDA-5/RIG-I/MAVS response induces interferon signaling, which further limits cellular proliferation. Staining of VCM3 WT & KO FL cells with the dsRNA-specific J2 antibody directly demonstrated significant accumulation of dsRNA in KO FL cells. We further demonstrated activation of the OAS/RNaseL axis in KO cells by quantification of tRNA-His-36 cleavage, which acts as a sensitive marker of RNase L activity. Phosphorylation of both PKR and eIF2a in KO cells demonstrated enhanced activity of this pathway. Lastly, we found a significant upregulation of interferon pathway genes in KO cells, and demonstrated that CRISPR mediated knockout of Mavs in VCM3 KO FL cells diminishes the activity of interferon response genes and rescues the Mettl3 KO phenotype in colony forming unit (CFU) assays. These results suggest that in the absence of m6A, endogenous dsRNA formation is enhanced, resulting in an associated inflammatory response which partially accounts for the hematopoietic defect observed in Mettl3 KO mice. In conclusion, our study suggests a novel, protective role for the m6A RNA modification in preventing endogenous dsRNA formation and aberrant activation of a detrimental innate immune response during mammalian hematopoietic development. Fan:IsoPlexis: Other: served on the scientific discovery board, Patents & Royalties; Singleron Biotechnologies: Other: served on the Scientific Advisory Board; BioTechne: Other: served on the Scientific Advisory Board. Flavell:Rheos Biomedicines: Equity Ownership; GSK: Consultancy; Artizan Biosciences: Equity Ownership; Troy: Equity Ownership; SMOC: Equity Ownership; Zai labs: Consultancy.
Author Xiao, Andrew
Song, Yuanbin
Joshi, Poorval
Biancon, Giulia
Liu, Wei
Ardasheva, Anastasia
Gao, Yimeng
Fan, Rong
Kudo, Eriko
Teng, Rhea
Li, Hua-Bing
Lee, Veronica
Viero, Gabriella
Tebaldi, Toma
Dura, Burak
Vasic, Radovan
Wang, Xiaman
Halene, Stephanie
Nelakanti, Raman
Fu, Xiaoying
Gbyli, Rana
Flavell, Richard
Iwasaki, Akiko
Author_xml – sequence: 1
  givenname: Yimeng
  surname: Gao
  fullname: Gao, Yimeng
  organization: Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT
– sequence: 2
  givenname: Radovan
  surname: Vasic
  fullname: Vasic, Radovan
  organization: Yale University School of Medicine, New Haven, CT
– sequence: 3
  givenname: Yuanbin
  surname: Song
  fullname: Song, Yuanbin
  organization: Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT
– sequence: 4
  givenname: Rhea
  surname: Teng
  fullname: Teng, Rhea
  organization: Yale University School of Medicine, New Haven, CT
– sequence: 5
  givenname: Rana
  surname: Gbyli
  fullname: Gbyli, Rana
  organization: Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT
– sequence: 6
  givenname: Giulia
  surname: Biancon
  fullname: Biancon, Giulia
  organization: Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT
– sequence: 7
  givenname: Raman
  surname: Nelakanti
  fullname: Nelakanti, Raman
  organization: Yale University School of Medicine, New Haven, CT
– sequence: 8
  givenname: Eriko
  surname: Kudo
  fullname: Kudo, Eriko
  organization: Yale University School of Medicine, New Haven, CT
– sequence: 9
  givenname: Wei
  surname: Liu
  fullname: Liu, Wei
  organization: Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT
– sequence: 10
  givenname: Anastasia
  surname: Ardasheva
  fullname: Ardasheva, Anastasia
  organization: Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT
– sequence: 11
  givenname: Xiaoying
  surname: Fu
  fullname: Fu, Xiaoying
  organization: Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT
– sequence: 12
  givenname: Xiaman
  surname: Wang
  fullname: Wang, Xiaman
  organization: Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT
– sequence: 13
  givenname: Poorval
  surname: Joshi
  fullname: Joshi, Poorval
  organization: Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT
– sequence: 14
  givenname: Burak
  surname: Dura
  fullname: Dura, Burak
  organization: Yale University, New Haven, CT
– sequence: 15
  givenname: Veronica
  surname: Lee
  fullname: Lee, Veronica
  organization: Yale University School of Medicine, New Haven, CT
– sequence: 16
  givenname: Gabriella
  surname: Viero
  fullname: Viero, Gabriella
  organization: Institute of Biophysics, CNR, Trento, Italy
– sequence: 17
  givenname: Akiko
  surname: Iwasaki
  fullname: Iwasaki, Akiko
  organization: Yale University School of Medicine, New Haven, CT
– sequence: 18
  givenname: Rong
  surname: Fan
  fullname: Fan, Rong
  organization: Yale University, New Haven, CT
– sequence: 19
  givenname: Andrew
  surname: Xiao
  fullname: Xiao, Andrew
  organization: Yale University School of Medicine, New Haven, CT
– sequence: 20
  givenname: Richard
  surname: Flavell
  fullname: Flavell, Richard
  organization: Department of Immunobiology, Yale University School of Medicine, New Haven, CT
– sequence: 21
  givenname: Hua-Bing
  surname: Li
  fullname: Li, Hua-Bing
  organization: Shanghai Institute of Immunology, Shanghai, China
– sequence: 22
  givenname: Toma
  surname: Tebaldi
  fullname: Tebaldi, Toma
  organization: Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT
– sequence: 23
  givenname: Stephanie
  surname: Halene
  fullname: Halene, Stephanie
  organization: Section of Hematology, Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale Univ. School of Medicine, New Haven, CT
BookMark eNp9kMtOwzAQRS1UJNrCB7DzDwTGzlusqtLSSClIJXsrsSeSUWJXcYLEng_HoaxZzSzuuZo5K7Iw1iAh9wweGMv4Y9NZqwIOLA9YCFHEr8iSxTwLADgsyBIAkiDKU3ZDVs59ALAo5PGSfJfWOWpbetxVVRnSIypdj6hon2zo6XVDj1bpVst61NbQE7qpGx3Vhj7bqekweB-H2iifn7OFUZP0e2GM76BF308GZ-hsjUPqg_SAfT3as9U4akn3te6mAW_JdVt3Du_-5ppU-121PQTl20ux3ZSBzCMeZEmCiudxkgDnSjVplMpQgUqbPGwgghgwTzGJWdbwpk0aZGnMUMqap5xzyMI1YZdaOfinB2zFedB9PXwJBmK2KH4titmiuFj0zNOFQX_Xp8ZBOKnR-C_1gHIUyup_6B-8fnuW
ContentType Journal Article
Copyright 2019 American Society of Hematology
Copyright_xml – notice: 2019 American Society of Hematology
DBID 6I.
AAFTH
AAYXX
CITATION
DOI 10.1182/blood-2019-130442
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
Anatomy & Physiology
EISSN 1528-0020
EndPage 450
ExternalDocumentID 10_1182_blood_2019_130442
S0006497118583683
GroupedDBID ---
-~X
.55
1CY
23N
2WC
34G
39C
4.4
53G
5GY
5RE
5VS
6I.
6J9
AAEDW
AAFTH
AAXUO
ABOCM
ABVKL
ACGFO
ADBBV
AENEX
AFOSN
AHPSJ
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
EX3
F5P
FDB
FRP
GS5
GX1
IH2
K-O
KQ8
L7B
LSO
MJL
N9A
OK1
P2P
R.V
RHF
RHI
ROL
SJN
THE
TR2
TWZ
W2D
W8F
WH7
WOQ
WOW
X7M
YHG
YKV
ZA5
0R~
AALRI
AAYXX
ACVFH
ADCNI
ADVLN
AEUPX
AFETI
AFPUW
AGCQF
AIGII
AITUG
AKBMS
AKRWK
AKYEP
CITATION
H13
ID FETCH-LOGICAL-c942-866ed29566022ddb747c3d0d7b93b04050e97e6518b2bf6be1751ecca27222083
ISSN 0006-4971
IngestDate Tue Jul 01 02:34:05 EDT 2025
Fri Feb 23 02:43:19 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Supplement_1
Language English
License This article is made available under the Elsevier license.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c942-866ed29566022ddb747c3d0d7b93b04050e97e6518b2bf6be1751ecca27222083
OpenAccessLink https://dx.doi.org/10.1182/blood-2019-130442
PageCount 1
ParticipantIDs crossref_primary_10_1182_blood_2019_130442
elsevier_sciencedirect_doi_10_1182_blood_2019_130442
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-11-13
PublicationDateYYYYMMDD 2019-11-13
PublicationDate_xml – month: 11
  year: 2019
  text: 2019-11-13
  day: 13
PublicationDecade 2010
PublicationTitle Blood
PublicationYear 2019
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
SSID ssj0014325
Score 2.3086123
Snippet Hematopoietic stem cell (HSC) self-renewal and lineage output are orchestrated by multiple regulatory layers, including RNA modifications. N6-methyladenosine...
SourceID crossref
elsevier
SourceType Index Database
Publisher
StartPage 450
Title Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure
URI https://dx.doi.org/10.1182/blood-2019-130442
Volume 134
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIh4XBCmI8tIcEAcig19ZO8e0apVCW4lgUHuydr1rFCm1qzapVM78GH5mZ3bXidOHRLk4zspZO5kv89j9Zoax90KUslQi9BS-erFUwpNRJL2-kOiM6ASNEOUO7x_w0Y_4y2H_sNP522ItzWfyU_H7xryS_5EqjqFcKUv2DpJdTIoDeI7yxSNKGI__JOM9tHCGw7KdZXuR2XQR5EEe82FvfDCkRmfEBLIyHuuz-XRm6K_oNcup9qgyLS2Am2uphwdxAXarCufo7VLeCPV0MBRau8cwovqu9Uk9ocTH3o6YTF05ksWu8NS1njeMHmFWYY-ofcCvZvCnQFQYsQpVny-R-d0xg4_mopKTJTlY2-Exmoz2-kQwoEQ9m1660Lmc-thZBGmnZqkuth_6K3rYrWpawJmmpmaFNA9aCja2ZWqdrXbvrpuBlMrKWuq_fabIj20Vr9WS21dM4YKgaEKjNMzNFDlNkdsp7rH7IQYkpFG_flvuV8VRaHtluO_q9s9xis_XnuJmD6jl1WRP2RMXjsDQYusZ6-iqy9aHCIH6-AI-gCEIm52XLnuw2Zw92mraBHbZw33HzlhnfwiPUJdg8QgNHgHxCIgxaOMRHB5hUsEVPJprHR7B4hEsHqHBI-CFsIJHcHh8zrKd7Wxr5LkuH14xiNEac65ViFE6R29SKYnhbREpXyVyEEm0MH1fDxLN-0EqQ1lyqdHfDUjvhAm6thhAvGBrVV3plwyUj7F5KYk1m8RlwFPFU5EUQemnhZCy2GAfmx8-P7G1XPJbBb3B4kY0uXNGrZOZI8hu_9iru9zjNXu8_Me8YWuz07l-iz7uTL4z8LoE2VClaA
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Loss+of+METTL3+Mediated+m6A+RNA+Modification+Results+in+Double-Stranded+RNA+Induced+Innate+Immune+Response+and+Hematopoietic+Failure&rft.jtitle=Blood&rft.au=Gao%2C+Yimeng&rft.au=Vasic%2C+Radovan&rft.au=Song%2C+Yuanbin&rft.au=Teng%2C+Rhea&rft.date=2019-11-13&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=134&rft.issue=Supplement_1&rft.spage=450&rft.epage=450&rft_id=info:doi/10.1182%2Fblood-2019-130442&rft.externalDBID=n%2Fa&rft.externalDocID=10_1182_blood_2019_130442
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon